<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Fulgent Genetics, Inc. — News on 6ix</title>
<link>https://6ix.com/company/fulgent-genetics-inc</link>
<description>Latest news and press releases for Fulgent Genetics, Inc. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Fri, 01 May 2026 11:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/fulgent-genetics-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo68356dee78dffbe2df0f39e9.webp</url>
<title>Fulgent Genetics, Inc.</title>
<link>https://6ix.com/company/fulgent-genetics-inc</link>
</image>
<item>
<title>Fulgent Reports First Quarter 2026 Financial Results</title>
<link>https://6ix.com/company/fulgent-genetics-inc/news/fulgent-reports-first-quarter-2026-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/fulgent-genetics-inc/news/fulgent-reports-first-quarter-2026-financial-results</guid>
<pubDate>Fri, 01 May 2026 11:00:00 GMT</pubDate>
<description>EL MONTE, Calif., May 01, 2026--Fulgent Genetics, Inc. (NASDAQ: FLGT) ("Fulgent," or the "Company"), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced financial results for its first quarter ended March 31, 2026.</description>
</item>
<item>
<title>Fulgent Selected to Present Rapid Oral Abstract Within the Head and Neck Cancer Track Session at the 2026 ASCO Annual Meeting</title>
<link>https://6ix.com/company/fulgent-genetics-inc/news/fulgent-selected-to-present-rapid-oral-abstract-within-the-head-and-neck-cancer-track-session-at-the-2026-asco-annual-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/fulgent-genetics-inc/news/fulgent-selected-to-present-rapid-oral-abstract-within-the-head-and-neck-cancer-track-session-at-the-2026-asco-annual-meeting</guid>
<pubDate>Wed, 22 Apr 2026 20:05:00 GMT</pubDate>
<description>EL MONTE, Calif., April 22, 2026--Fulgent Genetics, Inc. (NASDAQ: FLGT) ("Fulgent" or the "Company"), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that its abstract was selected to be presented within the Head and Neck Cancer Track of the American Society of Clinical Oncology (ASCO) rapid oral abstract session on June 1, 2026, from 4:30pm to 6:00pm (CDT) in hall D1 of McCormick Place, Chicago.</description>
</item>
<item>
<title>Fulgent to Announce First Quarter 2026 Financial Results on Friday, May 1, 2026</title>
<link>https://6ix.com/company/fulgent-genetics-inc/news/fulgent-to-announce-first-quarter-2026-financial-results-on-friday-may-1-2026</link>
<guid isPermaLink="true">https://6ix.com/company/fulgent-genetics-inc/news/fulgent-to-announce-first-quarter-2026-financial-results-on-friday-may-1-2026</guid>
<pubDate>Thu, 16 Apr 2026 11:30:00 GMT</pubDate>
<description>EL MONTE, Calif., April 16, 2026--Fulgent Genetics, Inc. (NASDAQ: FLGT) ("Fulgent" or the "Company"), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it will release its first quarter 2026 financial results before the market opens on Friday, May 1, 2026. Management will host a conference call for the investment community the same day at 8:30 AM ET (5:30 AM PT) to discuss the results and answer questions.</description>
</item>
<item>
<title>Fulgent Genetics Completes Acquisition of Bako Diagnostics and StrataDx</title>
<link>https://6ix.com/company/fulgent-genetics-inc/news/fulgent-genetics-completes-acquisition-of-bako-diagnostics-and-stratadx</link>
<guid isPermaLink="true">https://6ix.com/company/fulgent-genetics-inc/news/fulgent-genetics-completes-acquisition-of-bako-diagnostics-and-stratadx</guid>
<pubDate>Tue, 17 Mar 2026 04:00:00 GMT</pubDate>
<description>EL MONTE, Calif.--(BUSINESS WIRE)-- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent”), a technology-based company with a well-established laboratory services</description>
</item>
<item>
<title>Fulgent Reports Fourth Quarter and Full Year 2025 Financial Results</title>
<link>https://6ix.com/company/fulgent-genetics-inc/news/fulgent-reports-fourth-quarter-and-full-year-2025-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/fulgent-genetics-inc/news/fulgent-reports-fourth-quarter-and-full-year-2025-financial-results</guid>
<pubDate>Fri, 27 Feb 2026 05:00:00 GMT</pubDate>
<description>Revenue of $83.3 million, growing 9% year-over-year GAAP gross profit of $32.6 million, or GAAP gross margin of 39.1%; Non-GAAP gross profit of $34.2</description>
</item>
<item>
<title>Fulgent to Announce Fourth Quarter and Full Year 2025 Financial Results on Friday, February 27, 2026</title>
<link>https://6ix.com/company/fulgent-genetics-inc/news/fulgent-announce-fourth-quarter-full-123000916</link>
<guid isPermaLink="true">https://6ix.com/company/fulgent-genetics-inc/news/fulgent-announce-fourth-quarter-full-123000916</guid>
<pubDate>Thu, 12 Feb 2026 12:30:00 GMT</pubDate>
<description>EL MONTE, Calif., February 12, 2026--Fulgent Genetics, Inc. (NASDAQ: FLGT) ("Fulgent" or the "Company"), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it will release its fourth quarter and full year 2025 financial results before the market opens on Friday, February 27, 2026. Management will host a conference call for the investment community the same day at 8:30 AM ET (5:30 AM PT) to discuss the resul</description>
</item>
<item>
<title>Fulgent Genetics Agrees to Acquire Bako Diagnostics and StrataDx</title>
<link>https://6ix.com/company/fulgent-genetics-inc/news/fulgent-genetics-agrees-acquire-bako-diagnostics-and-stratadx-2025-12-22</link>
<guid isPermaLink="true">https://6ix.com/company/fulgent-genetics-inc/news/fulgent-genetics-agrees-acquire-bako-diagnostics-and-stratadx-2025-12-22</guid>
<pubDate>Mon, 22 Dec 2025 05:00:00 GMT</pubDate>
<description>Proposed acquisition will add new anatomic pathology services, proprietary PCR tests and a national client base EL MONTE, Calif.--(BUSINESS WIRE)-- Fulgent</description>
</item>
<item>
<title>Fulgent to Participate in Upcoming Conferences</title>
<link>https://6ix.com/company/fulgent-genetics-inc/news/fulgent-participate-upcoming-conferences-2025-11-07</link>
<guid isPermaLink="true">https://6ix.com/company/fulgent-genetics-inc/news/fulgent-participate-upcoming-conferences-2025-11-07</guid>
<pubDate>Fri, 07 Nov 2025 05:00:00 GMT</pubDate>
<description>EL MONTE, Calif.--(BUSINESS WIRE)-- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established</description>
</item>
<item>
<title>Fulgent Reports Third Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/fulgent-genetics-inc/news/fulgent-reports-third-quarter-2025-financial-results-2025-11-07</link>
<guid isPermaLink="true">https://6ix.com/company/fulgent-genetics-inc/news/fulgent-reports-third-quarter-2025-financial-results-2025-11-07</guid>
<pubDate>Fri, 07 Nov 2025 05:00:00 GMT</pubDate>
<description>Revenue of $84.1 million, growing 17% year-over-year Raising Full Year 2025 Revenue Guidance to $325.0 million Raising Full Year 2025 EPS Guidance to GAAP</description>
</item>
<item>
<title>Fulgent Shares Preliminary Data from Poster Presentation at ESMO 2025 Conference</title>
<link>https://6ix.com/company/fulgent-genetics-inc/news/fulgent-shares-preliminary-data-poster-presentation-esmo-2025-conference-2025-10-20</link>
<guid isPermaLink="true">https://6ix.com/company/fulgent-genetics-inc/news/fulgent-shares-preliminary-data-poster-presentation-esmo-2025-conference-2025-10-20</guid>
<pubDate>Mon, 20 Oct 2025 04:00:00 GMT</pubDate>
<description>EL MONTE, Calif.--(BUSINESS WIRE)-- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established</description>
</item>
<item>
<title>Fulgent to Announce Third Quarter 2025 Financial Results on Friday, November 7, 2025</title>
<link>https://6ix.com/company/fulgent-genetics-inc/news/fulgent-announce-third-quarter-2025-financial-results-friday-november-7-2025-2025-10</link>
<guid isPermaLink="true">https://6ix.com/company/fulgent-genetics-inc/news/fulgent-announce-third-quarter-2025-financial-results-friday-november-7-2025-2025-10</guid>
<pubDate>Thu, 16 Oct 2025 04:00:00 GMT</pubDate>
<description>EL MONTE, Calif.--(BUSINESS WIRE)-- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established</description>
</item>
<item>
<title>Fulgent Reports Second Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/fulgent-genetics-inc/news/fulgent-reports-second-quarter-2025-financial-results-2025-08-01</link>
<guid isPermaLink="true">https://6ix.com/company/fulgent-genetics-inc/news/fulgent-reports-second-quarter-2025-financial-results-2025-08-01</guid>
<pubDate>Fri, 01 Aug 2025 04:00:00 GMT</pubDate>
<description>Core Revenue of $81.7 million grows 16% year-over-year Raising Full Year 2025 Core Revenue Guidance to $320 million GAAP gross profit of $34.4 million, or</description>
</item>
<item>
<title>Fulgent Genetics Receives EU CE Mark for FulgentExome & FulgentPLM</title>
<link>https://6ix.com/company/fulgent-genetics-inc/news/fulgent-genetics-receives-eu-ce-mark-fulgentexome-fulgentplm-2025-07-17</link>
<guid isPermaLink="true">https://6ix.com/company/fulgent-genetics-inc/news/fulgent-genetics-receives-eu-ce-mark-fulgentexome-fulgentplm-2025-07-17</guid>
<pubDate>Thu, 17 Jul 2025 04:00:00 GMT</pubDate>
<description>EL MONTE, Calif.--(BUSINESS WIRE)-- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established</description>
</item>
<item>
<title>Fulgent to Announce Second Quarter 2025 Financial Results on Friday, August 1, 2025</title>
<link>https://6ix.com/company/fulgent-genetics-inc/news/fulgent-announce-second-quarter-2025-financial-results-friday-august-1-2025-2025-07</link>
<guid isPermaLink="true">https://6ix.com/company/fulgent-genetics-inc/news/fulgent-announce-second-quarter-2025-financial-results-friday-august-1-2025-2025-07</guid>
<pubDate>Thu, 10 Jul 2025 04:00:00 GMT</pubDate>
<description>EL MONTE, Calif.--(BUSINESS WIRE)-- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established</description>
</item>
<item>
<title>Fulgent Reports First Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/fulgent-genetics-inc/news/fulgent-reports-first-quarter-2025-financial-results-2025-05-02</link>
<guid isPermaLink="true">https://6ix.com/company/fulgent-genetics-inc/news/fulgent-reports-first-quarter-2025-financial-results-2025-05-02</guid>
<pubDate>Fri, 02 May 2025 04:00:00 GMT</pubDate>
<description>Core Revenue of $73.5 million grows 16% year-over-year Reiterating Full Year 2025 Core Revenue Guidance of $310 million Non-GAAP income of $1.2 million, or</description>
</item>
<item>
<title>Fulgent to Announce First Quarter 2025 Financial Results on Friday, May 2, 2025</title>
<link>https://6ix.com/company/fulgent-genetics-inc/news/fulgent-announce-first-quarter-2025-financial-results-friday-may-2-2025-2025-04-10</link>
<guid isPermaLink="true">https://6ix.com/company/fulgent-genetics-inc/news/fulgent-announce-first-quarter-2025-financial-results-friday-may-2-2025-2025-04-10</guid>
<pubDate>Thu, 10 Apr 2025 04:00:00 GMT</pubDate>
<description>EL MONTE, Calif.--(BUSINESS WIRE)-- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established</description>
</item>
<item>
<title>Fulgent Reports Fourth Quarter and Full Year 2024 Financial Results</title>
<link>https://6ix.com/company/fulgent-genetics-inc/news/fulgent-reports-fourth-quarter-and-full-year-2024-financial-results-2025-02-28</link>
<guid isPermaLink="true">https://6ix.com/company/fulgent-genetics-inc/news/fulgent-reports-fourth-quarter-and-full-year-2024-financial-results-2025-02-28</guid>
<pubDate>Fri, 28 Feb 2025 05:00:00 GMT</pubDate>
<description>Full Year Total Revenue of $283.5 million Full Year Core Revenue grows 7% year-over-year to $281.2 million Ended 2024 with $828.6 million of cash, cash</description>
</item>
<item>
<title>Fulgent to Announce Fourth Quarter and Full Year 2024 Financial Results on Friday, February 28, 2025</title>
<link>https://6ix.com/company/fulgent-genetics-inc/news/fulgent-announce-fourth-quarter-and-full-year-2024-financial-results-friday-february</link>
<guid isPermaLink="true">https://6ix.com/company/fulgent-genetics-inc/news/fulgent-announce-fourth-quarter-and-full-year-2024-financial-results-friday-february</guid>
<pubDate>Thu, 06 Feb 2025 05:00:00 GMT</pubDate>
<description>EL MONTE, Calif.--(BUSINESS WIRE)-- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established</description>
</item>
<item>
<title>Fulgent Reports Third Quarter 2024 Financial Results</title>
<link>https://6ix.com/company/fulgent-genetics-inc/news/fulgent-reports-third-quarter-2024-financial-results-2024-11-08</link>
<guid isPermaLink="true">https://6ix.com/company/fulgent-genetics-inc/news/fulgent-reports-third-quarter-2024-financial-results-2024-11-08</guid>
<pubDate>Fri, 08 Nov 2024 05:00:00 GMT</pubDate>
<description>Total Revenue of $71.7 million Core Revenue grows 9% year-over-year to $71.7 million Reiterates Full Year 2024 Core Revenue Guidance of $280 million,</description>
</item>
<item>
<title>Fulgent Genetics Awarded Contract by the U.S. Department of Veterans Affairs to Provide Hereditary Cancer, Pharmacogenetic and Other Genetic Testing to Veterans¹</title>
<link>https://6ix.com/company/fulgent-genetics-inc/news/fulgent-genetics-awarded-contract-us-department-veterans-affairs-provide-hereditary</link>
<guid isPermaLink="true">https://6ix.com/company/fulgent-genetics-inc/news/fulgent-genetics-awarded-contract-us-department-veterans-affairs-provide-hereditary</guid>
<pubDate>Thu, 31 Oct 2024 04:00:00 GMT</pubDate>
<description>EL MONTE, Calif.--(BUSINESS WIRE)-- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established</description>
</item>
</channel>
</rss>